InterK Peptide Therapeutics is focused on developing innovative peptide-based therapies to address significant unmet medical needs, particularly in oncology and immunology. The company’s research emphasizes the inhibition of cancer growth through three distinct compounds that share a common core amino acid sequence, derived from rational drug design based on receptor-MAP kinase interactions. These compounds not only demonstrate the ability to inhibit tumor growth in murine models but also exhibit varying immunomodulatory effects, influencing cytokine expression, cytokine receptors, and the regulation of signaling pathways in immune cells such as T cells and natural killer cells.

The company’s research initiatives target several critical areas, including the avoidance of autoimmune responses linked to immune checkpoint inhibitors, enhancing anti-cancer responses in metastatic cancer patients, and identifying peptide signatures for predicting patient responses to therapies. Additionally, InterK is exploring strategies to combat immune dysfunction related to aging, improve vaccine efficacy against viral infections, and address skin damage from UV radiation. Their work aims to balance immune responses while minimizing adverse effects, as highlighted in recent scientific publications.

Australia

InterK Peptide Therapeutics functions largely as a virtual company and located in Sydney, Australia.The company’s R&D program is supported by Contract Research Organisations located within Australia and overseas. All three assets share the ability to inhibit cancer growth in vivo in murine models but also differ significantly in their respective immunomodulating effects on expression of cytokines, cytokine receptors and regulation of signalling pathways within T cells, natural killer cells and antigen-presenting cells. 

InterK Peptide Therapeutics

Company Details